$ABUS News

Arbutus Biopharma Q1 EPS $0.87 Beats $(0.04) Estimate, Sales $179.126M Beat $750.000K Estimate

Arbutus Biopharma: A Fascinating HBV Story, But Still Too Early

Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B

Arbutus Biopharma shares are trading higher after the FDA granted the company Fast Track designation for imdusiran for the treatment of chronic hepatitis B

Arbutus Biopharma's Imdusiran Receives FDA's Fast Track Designation To Treat Chronic Hepatitis B

Arbutus: Q4 Earnings Snapshot

Arbutus Biopharma Q4 EPS $(0.01) Beats $(0.03) Estimate, Sales $1.051M Miss $1.233M Estimate

Staar Surgical Posts Downbeat Q4 Results, Joins Webtoon Entertainment, Gitlab And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Arbutus Biopharma: LNP Litigation And Imdusiran Drive Near-Term Catalysts

Arbutus Biopharma shares are trading lower after the Board of Appeal of the European Patent Office revoked the company's European patent.

Chardan Capital Maintains Buy on Arbutus Biopharma, Maintains $5 Price Target

Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Arbutus Biopharma Q3 EPS $(0.04) Misses $(0.03) Estimate, Sales $529.000K Miss $1.267M Estimate

Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025

Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates

Arbutus: Q2 Earnings Snapshot

Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Arbutus Biopharma Q2 EPS $0.01 Beats $(0.05) Estimate, Sales $10.74M Beat $1.59M Estimate

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

Arbutus Reacquires Greater China Rights To Imdusiran From Qilu, Forms Scientific Advisory Board Focused On Late-Stage Hepatitis B Trials